20 Years Experience of TNF-Based Isolated Limb Perfusion for In-Transit Melanoma Metastases: TNF Dose Matters

[1]  A. V. van Geel,et al.  Long‐term outcome of isolated limb perfusion with tumour necrosis factor‐α for patients with melanoma in‐transit metastases , 2011, The British journal of surgery.

[2]  A. Hauschild,et al.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.

[3]  E. Bastiaannet,et al.  TNF dose reduction and shortening of duration of isolated limb perfusion for locally advanced soft tissue sarcoma of the extremities is safe and effective in terms of long‐term patient outcome , 2011, Journal of surgical oncology.

[4]  K. Flaherty,et al.  Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.

[5]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[6]  S. Mocellin,et al.  Long-Term Results of Melphalan-Based Isolated Limb Perfusion With or Without Low-Dose TNF for In-Transit Melanoma Metastases , 2010, Annals of Surgical Oncology.

[7]  S. Steinberg,et al.  Analysis of factors influencing outcome in patients with in-transit malignant melanoma undergoing isolated limb perfusion using modern treatment parameters. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Jeffrey E Gershenwald,et al.  Final version of 2009 AJCC melanoma staging and classification. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  A. Hauschild,et al.  Surgery and radiotherapy in the treatment of cutaneous melanoma , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  N. Kandamany,et al.  Carbon dioxide laser ablation as first-line management of in-transit cutaneous malignant melanoma metastases , 2009, Lasers in Medical Science.

[11]  P. Kam,et al.  Outcomes Following Isolated Limb Infusion for Melanoma. A 14-Year Experience , 2008, Annals of Surgical Oncology.

[12]  A. Jemal,et al.  Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.

[13]  D Miklavcic,et al.  Electrochemotherapy in treatment of tumours. , 2008, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[14]  A. Eggermont,et al.  Hyperthermic isolated limb perfusion with tumor necrosis factor is a useful therapy for advanced melanoma of the limbs. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  J. Nagabhushan,et al.  Prognostic scoring in patients with melanoma after adjuvant isolated limb perfusion. , 2006, The Journal of surgical research.

[16]  Jeffrey E. Lee,et al.  Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  A. Eggermont,et al.  TNF dose reduction in isolated limb perfusion. , 2005, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[18]  J. Blay,et al.  Limb salvage with isolated perfusion for soft tissue sarcoma: could less TNF-α be better? , 2005 .

[19]  J. Blay,et al.  Limb salvage with isolated perfusion for soft tissue sarcoma: could less TNF-alpha be better? , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  A. Eggermont,et al.  One Hundred Consecutive Isolated Limb Perfusions With TNF-α and Melphalan in Melanoma Patients With Multiple In-Transit Metastases , 2004, Annals of surgery.

[21]  S. Mocellin,et al.  Hyperthermic Isolated Limb Perfusion With Low-Dose Tumor Necrosis Factor-α and Melphalan for Bulky In-Transit Melanoma Metastases , 2004, Annals of Surgical Oncology.

[22]  A. Eggermont,et al.  Prognostic factors for survival after isolated limb perfusion for malignant melanoma. , 2003, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[23]  M. Weichenthal,et al.  Prospective randomized trial of interferon alfa-2b and interleukin-2 as adjuvant treatment for resected intermediate- and high-risk primary melanoma without clinically detectable node metastasis. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  S. Steinberg,et al.  Factors Affecting Survival After Complete Response to Isolated Limb Perfusion in Patients With In-Transit Melanoma , 2001, Annals of Surgical Oncology.

[25]  A. Eggermont,et al.  Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion , 2000, British Journal of Cancer.

[26]  A. Eggermont,et al.  Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study. , 1999, Melanoma research.

[27]  R. Fisher,et al.  High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  A. Eggermont,et al.  Relation between limb toxicity and treatment outcomes after isolated limb perfusion for recurrent melanoma. , 1999, Journal of the American College of Surgeons.

[29]  A. Eggermont,et al.  Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats , 1999, British Journal of Cancer.

[30]  C. Wiltschke,et al.  Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  P. Schlag,et al.  Isolated limb perfusion with high-dose tumor necrosis factor-α for locally advanced extremity soft tissue sarcomas , 1997 .

[32]  P. Schlag,et al.  Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. , 1996, Annals of surgery.

[33]  B. Vrouenraets,et al.  Thirty‐five years of isolated limb perfusion for melanoma: Indications and results , 1996, The British journal of surgery.

[34]  A. Eggermont,et al.  Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  R. MacKie,et al.  A single centre's 10 year experience with isolated limb perfusion in the treatment of recurrent malignant melanoma of the limb. , 1996, European journal of cancer.

[36]  C. Garbe.  Perspectives of cytokine treatment in malignant skin tumors. , 1995, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[37]  J. Beijnen,et al.  Melphalan tissue concentrations in patients treated with regional isolated perfusion for melanoma of the lower limb. , 1994, British Journal of Cancer.

[38]  A. Eggermont,et al.  Patient- and treatment-related factors associated with acute regional toxicity after isolated perfusion for melanoma of the extremities. , 1993, American journal of surgery.

[39]  V. Ho,et al.  Pooled analysis of the efficacy of bacille Calmette-Guerin (BCG) immunotherapy in malignant melanoma. , 1993, The Journal of dermatologic surgery and oncology.

[40]  J. Thomas,et al.  Low‐dose tumour necrosis factor α and melphalan in hyperthermic isolated limb perfusion , 1993 .

[41]  J. Thomas,et al.  Low-dose tumour necrosis factor alpha and melphalan in hyperthermic isolated limb perfusion. , 1993, The British journal of surgery.

[42]  R. Mirimanoff,et al.  Regional therapy of melanoma. , 1993, European journal of cancer.

[43]  D. Coit,et al.  Major amputation for advanced malignant melanoma. , 1989, Surgery, gynecology & obstetrics.

[44]  S. Carlini,et al.  Prognostic variables in recurrent limb melanoma treated with hyperthermic antiblastic perfusion , 1989, Cancer.

[45]  A. V. van Geel,et al.  Regional perfusion treatment with melphalan for melanoma in a limb: an evaluation of drug kinetics. , 1988, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[46]  E. V. van Slooten,et al.  Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. , 1982, European journal of cancer & clinical oncology.

[47]  M. Palmer,et al.  WHO Handbook for Reporting Results of Cancer Treatment , 1982, British Journal of Cancer.

[48]  A. Miller,et al.  Reporting results of cancer treatment , 1981, Cancer.

[49]  R. D. Hunter,et al.  WHO Handbook for Reporting Results of Cancer Treatment , 1980 .

[50]  H. Ed,et al.  Biologic behavior and treatment of intransit metastasis of melanoma. , 1980 .

[51]  K. Choe,et al.  Biologic behavior and treatment of intransit metastasis of melanoma. , 1980, Surgery, gynecology & obstetrics.

[52]  R. F. Ryan,et al.  Chemotherapy of Cancer: Regional Perfusion Utilizing an Extracorporeal Circuit , 1958, Annals of surgery.

[53]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .